Report of Foreign Issuer (6-k)
February 11 2020 - 7:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For
the month of February 2020
Commission
File Number: 001-37643
KITOV
PHARMA LTD.
(Translation
of registrant’s name into English)
One
Azrieli Center, Round Tower,
132
Menachem Begin Road, Tel Aviv 6701101, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Kitov
Pharma Ltd. (the “Company” or the “Registrant”) is announcing that on February 10, 2019, the Company issued
a press release, “Kitov Pharma Provides Corporate Update and Reports Full-Year 2019 Financial Results”, which
is attached hereto as Exhibit 99.1.
The information contained within this report
on Form 6-K and all Exhibits attached hereto should be read in conjunction with (1) our Consolidated Unaudited Financial Statements
as of December 31, 2019, and for the year months then ended found in Exhibit 99.1 hereto; and, (2) our audited consolidated financial
statements for the year ended December 31, 2018, which appears in the Company’s Annual Report on Form
20-F filed with the Securities and Exchange Commission on March 26, 2019 (as amended by the Form
20-F/A amendment filed on April 3, 2019), as well as the other information contained in such Annual Report on Form 20-F and
in our Registration Statements and Prospectuses filed with the SEC.
The
IFRS financial statements in Exhibit 99.1, as well as the discussions concerning the IFRS financial measurements in the text which
is found under the headings entitled “Financial Results for the Year Ended December 31, 2019” and “Financial
Results for the 6 months Ended December 31, 2019” in Exhibit 99.1, are all hereby incorporated
by reference into each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission
on December 12, 2016 (Registration file numbers 333-207117 and 333-211477), the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s
Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number
333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange
Commission on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed
with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration
Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795)
and the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on December 2,
2019 (Registration file number 333- 333-235327), to be a part thereof from the date on which this report is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
KITOV
PHARMA LTD.
|
|
|
|
February
11, 2020
|
By:
|
/s/
Isaac Israel
|
|
|
Isaac
Israel
|
|
|
CEO
& Director
|
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Apr 2023 to Apr 2024